• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞毒性和免疫抑制性炎症细胞预测食管腺癌新辅助放化疗后的消退和预后。

Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma.

机构信息

Department of Gastroenterology, REGIOMED Klinikum Lichtenfels, Germany; University of Split, School of Medicine, Croatia.

Department of Nephropathology, Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.

出版信息

Radiother Oncol. 2020 May;146:151-160. doi: 10.1016/j.radonc.2020.02.003. Epub 2020 Mar 10.

DOI:10.1016/j.radonc.2020.02.003
PMID:32169773
Abstract

BACKGROUND AND PURPOSE

Tumour infiltrating lymphocytes (TIL) and tumour associated macrophages (TAM) play a key role in anticancer immunosurveillance. We studied their influence on response to neoadjuvant radiochemotherapy (RCT) and prognosis in patients with oesophageal adenocarcinoma (OAC).

MATERIALS AND METHODS

Between 10/2004 and 06/2018, pre-RCT biopsy-specimens were available from 76 patients with locally advanced, non-metastatic OAC scheduled for trimodality therapy. We evaluated intra- and peritumoural expression of FoxP3+-, CD8+-TIL and CD68+-, CD163+-TAM, contemplating cell density, cell ratios and cell-to-cell distances to determine a possible influence on tumour regression grade (TRG) and survival. Median follow-up time for all patients was 18 months (IQR 9-43), and 54 months (25-97) for surviving patients. Data were analysed using risk analysis, logrank test and Cox regression.

RESULTS

Poor tumour regression was detected for cN+ (RR 0.77 [95% CI 0.66-0.90], p = 0.001), low intratumoural FoxP3+/CD8+ ratio (RR 0.75 [0.60-0.96], p = 0.020), high peritumoural CD163+/CD68+ ratio (RR 0.77 [0.60-0.99], p = 0.045) and high intratumoural TAM density (RD -0.44 [-0.82 to -0.06], p = 0.023). Apart from poor resection quality and TRG, pretherapeutic high peritumoural CD8+ infiltration (HR 2.36 [1.21-4.61], p = 0.012) and short intratumoural FoxP3+ to CD8+ cell-to-cell distances in middle ranged CD8+ density (HR 2.55 [1.00-6.52], p = 0.050) were significant unfavourable prognostic factors in multivariate analysis.

CONCLUSIONS

Immunologic parameters, such as CD8+-, FoxP3+-TIL and CD68+-, CD163+-TAM, were identified to be of independent predictive and prognostic value in patients with OAC. Further and independent validation of these biomarkers by a large size dataset may urgently be contemplated.

摘要

背景与目的

肿瘤浸润淋巴细胞(TIL)和肿瘤相关巨噬细胞(TAM)在癌症免疫监视中起着关键作用。我们研究了它们在食管腺癌(OAC)患者新辅助放化疗(RCT)反应和预后中的影响。

材料和方法

2004 年 10 月至 2018 年 6 月期间,76 名局部晚期、无转移的 OAC 患者接受新辅助放化疗前的活检标本可用。我们评估了 FoxP3+、CD8+TIL 和 CD68+、CD163+TAM 的肿瘤内和肿瘤周围表达,考虑了细胞密度、细胞比例和细胞-细胞距离,以确定其对肿瘤消退分级(TRG)和生存的可能影响。所有患者的中位随访时间为 18 个月(IQR 9-43),存活患者的中位随访时间为 54 个月(25-97)。使用风险分析、对数秩检验和 Cox 回归分析数据。

结果

cN+(RR 0.77 [95%CI 0.66-0.90],p=0.001)、低肿瘤内 FoxP3+/CD8+比值(RR 0.75 [0.60-0.96],p=0.020)、高肿瘤周围 CD163+/CD68+比值(RR 0.77 [0.60-0.99],p=0.045)和高肿瘤内 TAM 密度(RD -0.44 [-0.82 至 -0.06],p=0.023)与肿瘤消退不良有关。除了切除质量差和 TRG 外,新辅助治疗前肿瘤周围 CD8+浸润高(HR 2.36 [1.21-4.61],p=0.012)和肿瘤内 FoxP3+到 CD8+细胞-细胞距离在中等 CD8+密度范围内(HR 2.55 [1.00-6.52],p=0.050)也是多变量分析中独立的不良预后因素。

结论

在 OAC 患者中,CD8+、FoxP3+TIL 和 CD68+、CD163+TAM 等免疫参数被确定为具有独立的预测和预后价值。通过大型数据集进一步和独立验证这些生物标志物可能迫在眉睫。

相似文献

1
Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma.细胞毒性和免疫抑制性炎症细胞预测食管腺癌新辅助放化疗后的消退和预后。
Radiother Oncol. 2020 May;146:151-160. doi: 10.1016/j.radonc.2020.02.003. Epub 2020 Mar 10.
2
PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma.程序性死亡受体1(PD-1)和程序性死亡配体1(PD-L1)的表达可预测食管腺癌新辅助放化疗后的肿瘤退缩情况及预后。
Clin Transl Radiat Oncol. 2022 Apr 3;34:90-98. doi: 10.1016/j.ctro.2022.04.001. eCollection 2022 May.
3
High CD8 tumour-infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapy.在新辅助放化疗反应不佳的食管腺癌中,高CD8肿瘤浸润淋巴细胞密度与不良预后相关。
Histopathology. 2021 Aug;79(2):238-251. doi: 10.1111/his.14361. Epub 2021 Apr 27.
4
High intratumoural but not peritumoural inflammatory host response is associated with better prognosis in primary resected oesophageal adenocarcinomas.肿瘤内而非肿瘤周围的高炎症宿主反应与原发性切除食管腺癌的较好预后相关。
Pathology. 2017 Jan;49(1):30-37. doi: 10.1016/j.pathol.2016.10.005. Epub 2016 Dec 2.
5
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.三阴性乳腺癌新辅助化疗后残留肿瘤中肿瘤浸润性CD8 +和FOXP3 +淋巴细胞的预后意义及这些参数的变化:一项回顾性多中心研究
Breast Cancer Res. 2015 Sep 4;17(1):124. doi: 10.1186/s13058-015-0632-x.
6
Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.肿瘤浸润 CD8+T 细胞与肿瘤相关 CD68+巨噬细胞联合预测可切除胃癌的术后预后和辅助化疗获益。
BMC Cancer. 2019 Sep 14;19(1):920. doi: 10.1186/s12885-019-6089-z.
7
Spatial distribution of FoxP3+ and CD8+ tumour infiltrating T cells reflects their functional activity.FoxP3+和CD8+肿瘤浸润性T细胞的空间分布反映了它们的功能活性。
Oncotarget. 2016 Sep 13;7(37):60383-60394. doi: 10.18632/oncotarget.11039.
8
CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.直肠癌放化疗前后CD8 +和FOXP3 +肿瘤浸润性T细胞
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21. doi: 10.1245/s10434-014-3584-y. Epub 2014 Feb 25.
9
[Changes in the CD8+ Density of Tumor Infiltrating Lymphocytes after Neoadjuvant Radiochemotherapy in Patients with Rectal Adenocarcinom].[直肠腺癌患者新辅助放化疗后肿瘤浸润淋巴细胞CD8+密度的变化]
Klin Onkol. 2016;29(3):204-9. doi: 10.14735/amko2016204.
10
[Prognostic value of tumor infiltration immune cells in pancreatic cancer].[肿瘤浸润免疫细胞在胰腺癌中的预后价值]
Zhonghua Wai Ke Za Zhi. 2018 Jun 1;56(6):464-470. doi: 10.3760/cma.j.issn.0529-5815.2018.06.015.

引用本文的文献

1
Prognostic immune markers in esophageal cancer patients managed with trimodal therapy.接受三联疗法治疗的食管癌患者的预后免疫标志物。
Cancer Immunol Immunother. 2025 Jan 3;74(2):57. doi: 10.1007/s00262-024-03891-3.
2
The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.食管腺癌肿瘤免疫微环境决定了新辅助治疗不同模式的结局 - 来自 AGITG DOCTOR 试验和癌症进化生物库的结果。
Front Immunol. 2023 Oct 12;14:1220129. doi: 10.3389/fimmu.2023.1220129. eCollection 2023.
3
PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma.
程序性死亡受体1(PD-1)和程序性死亡配体1(PD-L1)的表达可预测食管腺癌新辅助放化疗后的肿瘤退缩情况及预后。
Clin Transl Radiat Oncol. 2022 Apr 3;34:90-98. doi: 10.1016/j.ctro.2022.04.001. eCollection 2022 May.
4
Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma.术前肿瘤浸润 T 细胞影响食管腺癌新辅助放化疗的反应。
Oncoimmunology. 2021 Aug 4;10(1):1954807. doi: 10.1080/2162402X.2021.1954807. eCollection 2021.